Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 4A (JMJD2A) is a histone lysine demethylase that removes methyl groups from di- and trimethylated lysines on histone H3, primarily H3K9me2/3 and H3K36me2/3. It regulates chromatin structure and gene expression, acting as both a transcriptional repressor and a coactivator. JMJD2A is involved in various biological processes, including cell proliferation, differentiation, and tissue development, and it plays a role in diseases such as cancer and cardiac hypertrophy. It is considered a promising target for small-molecule inhibitors aimed at epigenetic therapy.
Inhibition of histone demethylase activity, leading to altered gene expression profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 4A (JMJD2A).